Harmony Biosciences CMO Sells $1.65M Shares

Harmony Biosciences CMO Sells $1.65M Shares

Budur Kumar, Chief Medical Officer of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY), disposed of 38,452 shares of the company’s common stock between 16 September and 18 September 2026. The shares were sold at prices ranging from $43.00 to $43.0545 per share, generating approximately $1.65 million in proceeds. The sales were executed pursuant to a Rule 10b5‑1 trading plan, allowing pre‑scheduled transactions to avoid insider‑trading concerns.

Concurrently, Kumar exercised stock options for an identical 38,452 shares at exercise prices between $30.27 and $30.69, resulting in an acquisition cost of roughly $1.17 million. The exercised options vest partially on 24 January 2025 (25 % of the underlying shares) with the balance vesting quarterly over four years, while other options vest initially on 1 May 2025. Following the sales and exercises, Kumar’s direct holding stands at 13,115 shares.

At the time of the transactions, HRMY was trading near its 52‑week high of $43.49, having delivered a 51 % total return over the preceding six months and trading at a price‑to‑earnings multiple of 13.96, according to InvestingPro.

In its second‑quarter 2026 earnings release, Harmony Biosciences reported adjusted earnings per share of $1.28, surpassing analysts’ consensus estimate of $0.878. Net sales reached a record $261.3 million, exceeding the consensus forecast of $250.8 million. The company reaffirmed its full‑year revenue guidance of $1.00 billion to $1.04 billion. Wolfe Research initiated coverage with an Outperform rating and a price target of $60.00, citing the resilience of the Wakix franchise despite ongoing intellectual‑property litigation and competitive pressures. Oppenheimer maintained an Outperform rating but reduced its price target from $85.00 to $70.00 following model updates. The earnings call also highlighted progress in the BP‑205 orexin‑2 program.